Theravance Biopharma annual total debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Theravance Biopharma Total Debt Growth & History (TBPH)
Theravance Biopharma's total debt was $42.7M for fiscal 2025.
View full Theravance Biopharma company overviewTheravance Biopharma annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $42.7M | −$7.1M | −14.29% |
| 2024 | 2024-12-31 | $49.8M | $661,000 | +1.34% |
| 2023 | 2023-12-31 | $49.2M | −$3.0M | −5.75% |
| 2022 | 2022-12-31 | $52.2M | −$617.4M | −92.21% |
| 2021 | 2021-12-31 | $669.5M | −$6.7M | −1.00% |
| 2020 | 2020-12-31 | $676.3M | $165.7M | +32.46% |
| 2019 | 2019-12-31 | $510.5M | $56.2M | +12.36% |
| 2018 | 2018-12-31 | $454.4M | $230.6M | +103.07% |
| 2017 | 2017-12-31 | $223.7M | — | — |
Theravance Biopharma quarterly total debt
Q4.17
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $38.6M | −$7.9M | −16.98% |
| Q1 2026 | 2026-03-31 | $40.5M | −$7.7M | −15.89% |
| Q4 2025 | 2025-12-31 | $42.7M | −$7.1M | −14.29% |
| Q3 2025 | 2025-09-30 | $44.6M | −$386,000 | −0.86% |
| Q2 2025 | 2025-06-30 | $46.5M | −$203,000 | −0.44% |
| Q1 2025 | 2025-03-31 | $48.2M | $253,000 | +0.53% |
| Q4 2024 | 2024-12-31 | $49.8M | $661,000 | +1.34% |
| Q3 2024 | 2024-09-30 | $45.0M | −$5.8M | −11.51% |
| Q2 2024 | 2024-06-30 | $46.7M | −$5.0M | −9.72% |
| Q1 2024 | 2024-03-31 | $47.9M | −$3.3M | −6.43% |
| Q4 2023 | 2023-12-31 | $49.2M | −$3.0M | −5.75% |
| Q3 2023 | 2023-09-30 | $50.8M | −$1.2M | −2.39% |
| Q2 2023 | 2023-06-30 | $51.7M | −$626.3M | −92.38% |
| Q1 2023 | 2023-03-31 | $51.2M | −$621.8M | −92.39% |
| Q4 2022 | 2022-12-31 | $52.2M | −$617.4M | −92.21% |
| Q3 2022 | 2022-09-30 | $52.1M | −$619.2M | −92.24% |
| Q2 2022 | 2022-06-30 | $678.0M | $9.6M | +1.44% |
| Q1 2022 | 2022-03-31 | $672.9M | $629,000 | +0.09% |
| Q4 2021 | 2021-12-31 | $669.5M | −$6.7M | −1.00% |
| Q3 2021 | 2021-09-30 | $671.2M | $613.7M | +1067.20% |
| Q2 2021 | 2021-06-30 | $668.3M | $611.9M | +1085.54% |
| Q1 2021 | 2021-03-31 | $672.3M | $617.2M | +1119.00% |
| Q4 2020 | 2020-12-31 | $676.3M | $165.7M | +32.46% |
| Q3 2020 | 2020-09-30 | $57.5M | $2.1M | +3.71% |
| Q2 2020 | 2020-06-30 | $56.4M | −$80,000 | −0.14% |
| Q1 2020 | 2020-03-31 | $55.2M | −$1.8M | −3.09% |
| Q4 2019 | 2019-12-31 | $510.5M | $56.2M | +12.36% |
| Q3 2019 | 2019-09-30 | $55.5M | — | — |
| Q2 2019 | 2019-06-30 | $56.5M | — | — |
| Q1 2019 | 2019-03-31 | $56.9M | — | — |
| Q4 2018 | 2018-12-31 | $454.4M | $230.6M | +103.07% |
| Q4 2017 | 2017-12-31 | $223.7M | — | — |
Theravance Biopharma total debt trends
Over the last five fiscal years, Theravance Biopharma's total debt decreased from $676.3M to $42.7M, a change of −$633.6M. The latest reported quarter, Q2 2026, shows $38.6M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Theravance Biopharma source filings ↗